Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu... (pabilitiespipeline and product portfolio...)

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

Date:5/15/2008

pabilities, pipeline and product portfolio in oncology and supportive care.

Eisai is committed to addressing the unmet medical needs of patients with cancer and to delivering novel treatment options that create hope.

About Aloxi Injection

Aloxi is approved by the U.S. FDA for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Aloxi is the first and only 5-HT(3) receptor antagonist to be indicated for the prevention of delayed CINV caused by moderately emetogenic cancer chemotherapy.

The most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components.

Please see the Aloxi package insert, available at http://www.aloxi.com, for important additional details.

About Gliadel Wafer

Gliadel (polifeprosan 20 with carmustine implant) Wafer is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery.

Gliadel should not be given to individuals who have demonstrated a previous hypersensitivity to carmustine or any of the components of Gliadel. Patients undergoing craniotomy for malignant glioma and implantation of Gliadel should be monitored closely for complications of craniotomy, including seizures, intracranial infections, abnormal wound healing and brain edema.

Communication between the surgical resection cavity and the ventricular system should be avoided to prevent the wafers from migrating into the ventricular system and causing obstructive hydrocephal
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. GeoVax Secures $10 Million Financing Commitment
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
6. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
7. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

Post Your Comments:

(Date:12/15/2009)... Estill Medical Technologies, Inc., a family-owned Texas ... IV Fluid Infusion Warmer , a patented medical device ... and emergency responders to lessen the ... 6 Unit of South Lake Tahoe as the first-ever ... Award." ,, CALSTAR is a California-based nonprofit ...

(Date:12/15/2009)... NASHVILLE, Tenn. and GLEN ROCK, N.J., Dec. 15 ... 70 percent of surveyed pharmacy directors expect to ... the treatment of chronic pain. Tanezumab, which is ... chronic pain and is administered intravenously under medical ... benefit rather than a pharmacy benefit according to ...

(Date:12/15/2009)... Dec. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... in China, announced today,that Weidong Yin, Chairman, ... Central,Television (CCTV) to be one of 18 ... CCTV,s Economic Man-of-the-Year is ... sometimes referred to as the "Oscar Award ...

Breaking Medicine Technology:Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 2 Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 3 Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 4 Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 2 Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 3 Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 2 Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 3 Genetic studies reveal new causes of severe obesity in childhood 62687 1 Genetic studies reveal new causes of severe obesity in childhood 62687 2 New FDA Approved Breast Cancer Screening Tool 6772 1 New FDA Approved Breast Cancer Screening Tool 6772 2 New FDA Approved Breast Cancer Screening Tool 6772 3 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 1 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 2 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 3 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 4 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 5 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 6 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 7 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 8 Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 62682 9

[0] Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award [0] Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain [0] Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award

... New Products Launched within the Last ... Revenue in 2006, PHILADELPHIA, Aug. 15 Thomson ... TSX: TOC) and leading provider,of information solutions to the ... Ones-to-Watch report, providing,expert insight into the five most promising ...

... Corporation,(Nasdaq: DNDN ) today announced publication of ... investigational active cellular immunotherapy, in the,August 20 issue ... highlights,the safety profile, immune response and clinical activity ... have failed standard,therapy. "In addition to demonstrating ...

Other Medicine Technology:Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline 2 Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline 3 Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline 4 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3 Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4

Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. As competitors ... complete a product portfolio they also must face ... ,, A new free, white paper from Howard ... Conservation Program: US Airways ," details how the ... the newly formed company to enhance its occupational ...

(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com ... report is available in its catalogue: ... Diseases Therapeutics - Market Forecasts to ... Deals Analysis ,, http://www.reportlinker.com/p0168098/The-Future-of-Cardiovascular-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... The author has released its latest ...

(Date:12/15/2009)... STAMFORD, Conn., Dec. 15 Aon ... of Aon Corporation (NYSE: AON ... the firm as senior vice president with ... of the national Pharmacy Practice. ,, ... her new role, Zeitel will work under ...

(Date:12/15/2009)... Research shows a direct correlation between effective workplace ... a culture of health improvement can result in ... new white paper from The Vitality Group, a ... an ideal setting for the delivery of health ... corporate culture of health is a critical component ...

(Date:12/15/2009)... -- Today, Coastal Healthcare Administrators officially announced ... the first time since its inception in ... will be assuming responsibilities and provider contracts ... Medical Care. ,, Operating on a ... working relationships with all network physicians, ancillary ...

[0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Aon Consulting Adds Senior Vice President to National Pharmacy Practice [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Coastal Healthcare Administrators Expands Provider Network to Santa Clara County

... raised about its autonomy, a high-level expert committee is confident ... "as immune as possible from authorities". ,"We hope ... AIIMS as immune as possible from authorities," M S Valiathan, ... committee on AIIMS affairs, told PTI from Manipal. ...

... associated with it begin at vessel branches and this ... which activate// a cellular protein that has been known ... link mechanical forces with structural and biochemical changes in ... form preferentially at branches of coronary arteries. ...

... a burning issue in Asian countries, especially with around ... ,Looking at the main causes of this condition, ... this growing condition is due to ignorance towards prevention ... found that the governments of some developing countries failed ...

... have time to attend support groups or can't afford the ... support for these mothers may be just a phone call ... Carolina College of Nursing researcher shows that regular phone calls ... are isolated because of their child’s illness and overwhelmed by ...

... Minster Anbumani Ramadoss has been pilloried back home for his ... of Medical Sciences (AIIMS), his// ministry has been honoured for ... ,The American Cancer Society has hailed India's Ministry of Health ... may aspire" and given it the award for Exemplary Leadership ...

... Recent research has revealed that gene mutations that are ... of Rett syndrome (RTT) in females are not always ... previous assumptions, and can occur sporadically in infant males ... published in the journal Neurology reports four sporadic occurrences ...

Other Medicine News:Health News:Atherosclerosis and its Mechanics 2 Health News:Atherosclerosis and its Mechanics 3 Health News:The Fight Against Hepatitis 2 Health News:Phone Calls Lend Vital Support to Moms of Mentally Ill Children 2 Health News:Phone Calls Lend Vital Support to Moms of Mentally Ill Children 3 Health News:Health Minister Ramadoss Honoured for his Exemplary Work 2 Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 2 Health News:Gene Mutations Causing Rett Syndrome Occur in Both Sexes 3

Expert panel confident of making AIIMS fully autonomous Atherosclerosis and its Mechanics The Fight Against Hepatitis Phone Calls Lend Vital Support to Moms of Mentally Ill Children Health Minister Ramadoss Honoured for his Exemplary Work Gene Mutations Causing Rett Syndrome Occur in Both Sexes

... Management software- RLISYS provides ... Software, Support, and Training ... Optometry, Ophthalmology, and Opticianry- ... operations, allowing you to ...

... The Advia 120 ... to streamline laboratory workflow ... benefits. This analyzer offers ... diagnostic assays, meeting the ...

The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis....

The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...

Medicine Products:

RLISYS Advia 120 K-4500 XT-1800i

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annu...(pabilitiespipeline and product portfolio...),Health